// App-Quantinova.ai

2595 : Pharmacokinetics (PK) of eribulin mesylate in cancer patients (pts) with normal and impaired renal function.

Researchers

Presenter

  • Antoinette R. Tan

Principal Investigators

  • John Sarantopoulos

  • Martin S. Olivo

  • Sanjay Goel

  • Lucy Lee

  • Larisa Reyderman

  • Yi He

Medical Centers

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, TXEisai, Woodcliff Lake, NJAlbert Einstein Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Creatinine

Drug/Treatment

  • Eribulin

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • NCT01418677

Sponsors

  • Eisai Co., Ltd.

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved